Archives
-
Dasatinib (BMS-354825) in Cancer Signaling Assays
2026-09-28
Use Dasatinib to probe Src- and Bcr-Abl-dependent signaling, then connect early kinase responses to later cellular phenotypes with matched controls. This workflow distinguishes established model-specific observations from exploratory testing of the SNAI1–PIK3R2/p-EphA2 axis in thymic tumors.
-
HyperFusion™ high-fidelity DNA polymerase for Assays
2026-09-27
Learn where PCR fits—and where it does not—in cell viability, proliferation, and cytotoxicity workflows. This scenario-driven guide explains how HyperFusion™ high-fidelity DNA polymerase (SKU K1032) can support accurate genotyping and sequence verification, with practical setup guidance for difficult templates.
-
Cy3 Goat Anti-Mouse IgG (H+L) Antibody Guide
2026-09-26
This Cy3-labeled secondary antibody detects mouse primary antibodies in fluorescence-based assays and western blot workflows, with secondary binding providing signal amplification. It is intended for research use; assay-specific working dilutions are not provided, and the azide-containing formulation is not suitable for unvalidated live-cell staining.
-
N-octanoyl-L-Homoserine lactone in Cell Signaling
2026-09-25
Use C8-HSL as a defined quorum-sensing signal to probe bacterial communication and test how microbial molecules influence host-cell behavior. This workflow connects dose-controlled exposure with orthogonal signaling, proliferation, migration, and invasion readouts—while separating practical assay suggestions from what has been demonstrated in lung cancer cells.
-
Removing Pollen Interference from EEM Bioaerosol Analysis
2026-09-25
Zhang et al. examined how pollen fluorescence can confound excitation–emission matrix classification of hazardous bioaerosol components. Their feature-transformation and random-forest approach achieved 89.24% reported accuracy across 31 sample types, with fast Fourier transform processing improving classification performance by 9.2% as reported by the authors.
-
LDN-193189 for BMP Signaling Workflow Design
2026-09-24
Use LDN-193189 to test how BMP type I receptor activity contributes to epithelial phenotypes, with acute Smad readouts and carefully separated stem-cell and differentiation endpoints. A practical workflow combines dose-and-time titration with pathway controls and highlights an important limitation: BMP inhibition may restore some lineage features without rebuilding the intestinal stem-cell pool.
-
α2-Adrenergic Receptor Agonist: Research Workflow
2026-09-24
Use 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine to investigate α2-adrenergic receptor signaling with a workflow that separates receptor effects from direct tumor-cell toxicity. The approach connects cell assays, immune readouts, and local hydrogel delivery while flagging the controls needed to interpret preclinical findings.
-
Neutrophil-Targeted mRNA Nanovaccine for Liver Cancer
2026-09-23
A biomimetic mRNA nanovaccine uses CD300LD-bearing tumor-cell membranes to direct IL-36γ expression toward tumor-associated neutrophils in hepatocellular carcinoma. The reported mouse findings support selective neutrophil reprogramming as a potential immunotherapy strategy, while leaving important questions about safety, targeting, and translation to human disease.
-
Rocilinostat (ACY-1215) Assay Workflows
2026-09-23
Build selective HDAC6-engagement assays around acetylated α-tubulin, multiple myeloma viability, and proteasome-inhibitor combination testing. A carefully bounded extension uses the SMPD4–ceramide study to design exploratory primary-cilia and neural-progenitor experiments without conflating distinct mechanisms.
-
Carfilzomib Sensitizes ESCC to Iodine-125 Radiation
2026-09-22
A 2025 Translational Oncology study shows that Carfilzomib, also known as PR-171, enhances iodine-125 seed radiation in esophageal squamous cell carcinoma by intensifying endoplasmic reticulum stress. The combination activated apoptosis, paraptosis, and ferroptosis through partially distinct mechanisms, providing a mechanistic framework for studying proteasome inhibition as a radiation-sensitization strategy.
-
Angiotensin II: Mechanism and Research Use
2026-09-22
Angiotensin II is an endogenous octapeptide and potent vasopressor that activates angiotensin GPCRs to regulate vascular tone, aldosterone release, and vascular remodeling. The article defines sequence identity, signaling mechanisms, product-specific handling, and research boundaries for vascular smooth muscle cell hypertrophy research and hypertension mechanism study.
-
Berberine Hydrochloride: Applied Research Workflows
2026-09-21
Berberine hydrochloride provides a practical AMPK-centered tool for connecting lipid metabolism modulation with mitochondrial and cell-death assays. This guide translates cardiotoxicity findings into formulation, cell-based, and translational workflows while distinguishing evidence-backed observations from exploratory dose and assay recommendations.
-
SC 79: Cytosolic Akt Activation in Cell Models
2026-09-21
SC 79 is an Akt activator that enables mechanistically focused studies of cytosolic Akt phosphorylation, neuronal survival, and pathway-specific assay design. This article distinguishes its neuroprotective evidence from mTORC1–IRE1α lipotoxicity research and defines practical boundaries for interpretation.
-
Azilsartan: Reading AT1 Signals in CNS Assays
2026-09-20
Azilsartan (TAK-536) is a precise pharmacological probe for interpreting AT1 receptor signaling in reactive astrocyte–microglia models. This article explains how to distinguish receptor-level causality from broader renin–angiotensin system effects and design more informative CNS inflammation assays.
-
SMPD4, Ceramide, and Primary Cilia Development
2026-09-19
A 2024 Development study connects SMPD4-dependent sphingomyelin metabolism to primary cilium maintenance, neural progenitor survival, and Purkinje cell development. By combining a mouse model with SMPD4-deficient human iPSC-derived neural cells and ceramide rescue, the work provides a mechanistic framework for SMPD4-associated microcephaly and cerebellar hypoplasia.